Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Chronic-Phase 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

nilotinib 12Imatinib Mesylate 10Dasatinib 3bosutinib 2asciminib 2flumatinib 1Interferons 1Growth Hormone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × flumatinib × Clear all
NCT05367765 2022-05-10

A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 4 Not yet recruiting
2,400 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡